Business Context and Reporting Period
This Form 8-K was filed by Pieris Pharmaceuticals, Inc. on October 17, 2017. The filing serves as a Regulation FD Disclosure regarding a significant clinical development milestone. Note: The request metadata references "Palvela Therapeutics," but the filing text explicitly identifies the registrant as Pieris Pharmaceuticals, Inc.
Key Financial Metrics
This filing is a current report regarding a clinical trial event and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes
The material change reported is the enrollment of the first patient in a multi-dose Phase IIa clinical study for the company's drug candidate, PRS-080.
Outlook, Management Commentary, and Risks
- Clinical Study Details: The study targets functional iron deficiency (FID) anemic patients with chronic kidney disease undergoing hemodialysis.
- Drug Candidate: PRS-080, an Anticalin protein targeting hepcidin.
- Study Design: Randomized, placebo-controlled study conducted in Germany and the Czech Republic.
- Dosing and Cohorts: Two dose cohorts (4 mg/kg and 8 mg/kg). Each cohort includes 4 patients receiving the drug and 2 patients on placebo.
- Regulatory Status: Clinical trial applications (CTAs) were previously filed with relevant authorities in the study regions.
Key Facts for Investor Verification
- Confirm the registrant name is Pieris Pharmaceuticals, Inc., not Palvela Therapeutics.
- Verify the specific patient population: chronic kidney disease patients on hemodialysis with functional iron deficiency.
- Monitor future filings for enrollment completion and preliminary data readouts from the Phase IIa study.
- Note that this filing contains no financial data; refer to the most recent 10-Q or 10-K for financial health metrics.